30% Disc. Pharmapoint: Osteoporosis - Global Drug Forecast and Market Analysis to 2022

August, 20, 2014 : Bharat Book Bureau Offers 30% discount on Premium Pharma Research Reports valid till this FRIDAY, 22nd, August, 2014. HURRY UP!!! Get insightful reports on pharma healthcare sectors covering Cardiovascular Diseases, Multiple Sclerosis,Oncology, Women's Health topics, Immunology and much more at unbelievable price tags.

Summary

Despite its maturity, the osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the ‘gold-standard’ bisphosphonates will lose patent protection by end-of-year 2013, flooding the marketplace with less expensive generic versions of these physician-preferred medications. Additionally, Eli Lilly’s blockbuster Evista, the only available SERM in the US, will lose patent protection in 2014, flooding the market with yet more affordable generic options. Also during the forecast period covered by this report, osteoporosis drug development research will lead to the launches of a wave of novel anabolic drugs with greater efficacy and safety, causing a major market shift away from anti-resorptive drugs. The number of companies vying for patient share will shrink by as much as 50%, as established players exit the market or acquire smaller players. Lastly, the aging of the population in developed markets will result in a larger patient pool.

Highlights

Key Questions Answered

- Bisphosphonates and selective estrogen receptor modulators (SERMs) dominate the osteoporosis market. However, unmet needs exist in terms of safety and efficacy. Will the drugs under development fulfill the unmet needs of the osteoporosis market?

- Six major brands are due to lose patent protection before 2015. How will these patent expiries as well as new product launches impact the osteoporosis therapeutics market?

- The developmental pipeline consists of several novel drugs. Which of these drugs will attain high sales revenues during 2012-2022? Which will have the highest peak sales at the highest...